Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2008 Feb 3;23(6):341–347. doi: 10.1007/s12264-007-0051-9

No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia

精神分裂症患者颞上回的大麻素受体密度没有显著性变化

Chao Deng 1,2,✉, Mei Han 1,2, Xu-Feng Huang 1,2
PMCID: PMC5550648  PMID: 18064064

Abstract

Objective

In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects.

Methods

Quantitative autoradiography was used to investigate the binding densities of [3H]SR141716A (a selective antagonist) and [3H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia).

Results

Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [3H]SR141716A and [3H]CP-55940 binding.

Conclusion

We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.

Keywords: schizophrenia, cannabinoid receptor, autoradiography, superior temporal gyrus

References

  • [1].Degenhardt L., Hall W. Cannabis and psychosis. Curr Psychiat Rep. 2002;4:191–196. doi: 10.1007/s11920-002-0026-5. [DOI] [PubMed] [Google Scholar]
  • [2].Skosnik P.D., Spatz-Glenn L., Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res. 2001;48:83–92. doi: 10.1016/S0920-9964(00)00132-8. [DOI] [PubMed] [Google Scholar]
  • [3].Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiat. 2001;58:322–328. doi: 10.1001/archpsyc.58.4.322. [DOI] [PubMed] [Google Scholar]
  • [4].Johns A. Psychiatric effects of cannabis. Brit J Psychiat. 2001;178:116–122. doi: 10.1192/bjp.178.2.116. [DOI] [PubMed] [Google Scholar]
  • [5].Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. doi: 10.1126/science.1470919. [DOI] [PubMed] [Google Scholar]
  • [6].Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686–691. doi: 10.1038/372686a0. [DOI] [PubMed] [Google Scholar]
  • [7].Emrich H.M., Leweke F.M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav. 1997;56:803–807. doi: 10.1016/S0091-3057(96)00426-1. [DOI] [PubMed] [Google Scholar]
  • [8].Ujike H., Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci. 2004;96:376–381. doi: 10.1254/jphs.FMJ04003X4. [DOI] [PubMed] [Google Scholar]
  • [9].Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665–1669. doi: 10.1097/00001756-199906030-00008. [DOI] [PubMed] [Google Scholar]
  • [10].Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkotter J., Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108–2114. doi: 10.1038/sj.npp.1300558. [DOI] [PubMed] [Google Scholar]
  • [11].Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001;103:9–15. doi: 10.1016/S0306-4522(00)00552-2. [DOI] [PubMed] [Google Scholar]
  • [12].Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiat. 2004;28:355–360. doi: 10.1016/j.pnpbp.2003.11.005. [DOI] [PubMed] [Google Scholar]
  • [13].Newell K.A., Deng C., Huang X.F. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res. 2006;172:556–560. doi: 10.1007/s00221-006-0503-x. [DOI] [PubMed] [Google Scholar]
  • [14].Kim J.J., Crespo-Facorro B., Andreasen N.C., O’Leary D.S., Magnotta V., Nopoulos P. Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: relationship to symptoms. Schizophr Res. 2003;60:173–181. doi: 10.1016/s0920-9964(02)00299-2. [DOI] [PubMed] [Google Scholar]
  • [15].Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience. 1997;77:299–318. doi: 10.1016/S0306-4522(96)00428-9. [DOI] [PubMed] [Google Scholar]
  • [16].Jablensky A., Hugler H., Von Cranach M., Kalinov K. Kraepelin revisited: a reassessment and statistical analysis of dementia praecox and manic-depressive insanity in 1908. Psychol Med. 1993;23:843–858. doi: 10.1017/S0033291700026337. [DOI] [PubMed] [Google Scholar]
  • [17].Keks N., Hill C., Opeskin K., Copolov D., Dean B. Psychiatric diagnosis after death: the problems of accurate diagnosis. In: Dean B., Hyde T.M., Kleinman J., editors. The Use of CNS Autopsy Tissue in Psychiatric Research: A Practical Guide. Sydney: Gordon & Breach Science Publishers; 1988. pp. 19–37. [Google Scholar]
  • [18].Newell K.A., Zavitsanou K., Jew S.K., Huang X.F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuro psychopharmacol Biol Psychiatry. 2007;31:225–233. doi: 10.1016/j.pnpbp.2006.07.004. [DOI] [PubMed] [Google Scholar]
  • [19].Oviedo A., Glowa J., Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 1993;616:293–302. doi: 10.1016/0006-8993(93)90220-H. [DOI] [PubMed] [Google Scholar]
  • [20].Rodriguez de Fonseca F., Gorriti M.A., Fernandez-Ruiz J.J., Palomo T., Ramos J.A. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav. 1994;47:33–40. doi: 10.1016/0091-3057(94)90108-2. [DOI] [PubMed] [Google Scholar]
  • [21].Sundram S., Copolov D., Dean B. Clozapine decreases [3H] CP55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedebergs Arch Pharmacol. 2005;371:428–433. doi: 10.1007/s00210-005-1074-2. [DOI] [PubMed] [Google Scholar]
  • [22].Gaser C., Nenadic I., Volz H.P., Buchel C., Sauer H. Neuroanatomy of “hearing voices”: a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb Cortex. 2004;14:91–96. doi: 10.1093/cercor/bhg107. [DOI] [PubMed] [Google Scholar]
  • [23].Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootoonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., Johnes T., Frackowiak R.S.J. A functional neuroanatomy of hallucination in schizophrenia. Nature. 1995;378:176–179. doi: 10.1038/378176a0. [DOI] [PubMed] [Google Scholar]
  • [24].Lennox B.R., Park S.B., Medley I., Morris P.G., Jones P.B. The functional anatomy of auditory hallucinations in schizophrenia. Psychiat Res. 2000;100:13–20. doi: 10.1016/S0925-4927(00)00068-8. [DOI] [PubMed] [Google Scholar]
  • [25].Voruganti L.N., Slomka P., Zabel P., Mattar A., Awad A.G. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiat Res. 2001;107:173–177. doi: 10.1016/S0925-4927(01)00104-4. [DOI] [PubMed] [Google Scholar]
  • [26].Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58:315–348. doi: 10.1016/S0301-0082(98)00087-2. [DOI] [PubMed] [Google Scholar]
  • [27].Vinod K.Y., Hungund B.L. Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2006;10:203–210. doi: 10.1517/14728222.10.2.203. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES